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Palmitate-Mediated Downregulation of Peroxisome
Proliferator–Activated Receptor- Coactivator 1 in
Skeletal Muscle Cells Involves MEK1/2 and Nuclear
Factor-B Activation
Teresa Coll, Mireia Jove ´, Ricardo Rodrı ´guez-Calvo, Elena Eyre, Xavier Palomer, Rosa M. Sa ´nchez,
Manuel Merlos, Juan Carlos Laguna, and Manuel Va ´zquez-Carrera
The mechanisms by which elevated levels of free fatty acids
cause insulin resistance are not well understood. Previous
studies have reported that insulin-resistant states are
characterized by a reduction in the expression of peroxi-
some proliferator–activated receptor- coactivator (PGC)-1,
a transcriptional activator that promotes oxidative capac-
ity in skeletal muscle cells. However, little is known about
the factors responsible for reduced PGC-1 expression. The
expression of PGC-1 mRNA levels was assessed in C2C12
skeletal muscle cells exposed to palmitate either in the
presence or in the absence of several inhibitors to study
the biochemical pathways involved. We report that expo-
sure of C2C12 skeletal muscle cells to 0.75 mmol/l palmi-
tate, but not oleate, reduced PGC-1 mRNA levels (66%;
P < 0.001), whereas PGC-1 expression was not affected.
Palmitate led to mitogen-activated protein kinase (MAPK)–
extracellular signal–related kinase (ERK) 1/2 (MEK1/2)
activation. In addition, pharmacological inhibition of this
pathway by coincubation of the palmitate-exposed cells
with the MEK1/2 inhibitors PD98059 and U0126 prevented
the downregulation of PGC-1. Furthermore, nuclear fac-
tor-B (NF-B) activation was also involved in palmitate-
mediated PGC-1 downregulation, since the NF-B
inhibitor parthenolide prevented a decrease in PGC-1
expression. These ﬁndings indicate that palmitate reduces
PGC-1 expression in skeletal muscle cells through a mech-
anism involving MAPK-ERK and NF-B activation.
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D
ifferent lines of evidence support the contention
that elevated plasma free fatty acids (FFAs) are
responsible for much of the insulin resistance
present in type 2 diabetic patients. In fact,
several studies (1–3) have consistently demonstrated that
elevated plasma FFA levels generate insulin resistance in
healthy subjects. Although insulin-resistant subjects ex-
hibit chronic increases in plasma FFAs, due in part to
excess lipolysis (4), their rates of fatty acid oxidation in
skeletal muscle are reduced (5). As a result of these
changes, fatty acids accumulate in skeletal muscle of
insulin-resistant subjects and lead to enhanced levels of
triglycerides (6), fatty acyl CoA (7), diacylglycerol (7), and
ceramides (8). It is worth noting that a positive correlation
has been reported between increased intramyocellular
triglyceride content and insulin resistance (9), suggesting
that prevention of lipid accumulation in skeletal muscle
may improve insulin resistance. Despite such data, it is not
known how elevated levels of FFAs result in lipid accu-
mulation in skeletal muscle cells.
Exposure of skeletal muscle cells to elevated FFAs may
affect the expression of several genes, contributing to the
development of insulin resistance. We (10) and other
researchers (11–13) have reported that insulin-resistant
states are characterized by a reduction in skeletal muscle
of peroxisome proliferator–activated receptor (PPAR)
coactivator-1 (PGC-1), the transcriptional coactivator driv-
ing the expression of many genes coding for proteins in
mitochondria. PGC-1 was initially identiﬁed as a protein
that interacted with PPAR (14). Several isoforms of
PGC-1 have been cloned, including PGC-1, PGC-1, and
the PGC-related coactivator (15). PGC-1 is highly ex-
pressed in tissues with high metabolic rates, such as the
heart, muscle, and brown adipose tissue (15). PGC-1 acts
as a transcriptional coactivator for PPARs and activates
the expression of genes involved in fatty acid metabolism.
It has recently been reported that lipid infusion decreases
the expression of nuclear encoded mitochondrial genes
and PGC-1 in human skeletal muscle (16). This discovery
suggests that enhanced lipid levels in plasma may be
responsible for the downregulation of PGC-1 in insulin-
resistant states. Consistent with this ﬁnding, it has been
reported that PGC-1 expression has been shown to be
inversely correlated with plasma FFA concentration (13).
However, nothing is yet known either about the kind of
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mechanisms involved. To gain a better understanding of
the mechanism by which skeletal muscle cell exposure to
fatty acids may result in PGC-1 downregulation, we used
the myoblast C2C12 cell line, which develops biochemical
and morphological properties characteristic of skeletal
muscle and which has been proven useful in studies of
skeletal muscle metabolism (17). Exposure of skeletal
muscle C2C12 cells to the saturated fatty acid palmitate,
but not to the monounsaturated fatty acid oleate, reduced
PGC-1 mRNA expression, whereas PGC-1 was not sig-
niﬁcantly affected. The mechanism by which palmitate
reduced the expression of PGC-1 seems to involve mito-
gen-activated protein kinase (MAPK)–extracellular signal–
related kinase (ERK) 1/2 (MEK1/2), since inhibition of this
pathway prevented PGC-1 downregulation. These results
identify high plasma levels of the saturated fatty acid
palmitate as one of the factors potentially contributing to
the downregulation of PGC-1 in skeletal muscle.
RESEARCH DESIGN AND METHODS
Anti–interleukin (IL)-6 antibody, C2-ceramide, ISP1, and pyrrolidine dithiocar-
bamate were obtained from Sigma (St. Louis, MO) and PD98059 and calphos-
tin C from Biomol Research Labs (Plymouth Meeting, PA). Other chemicals
were purchased from Sigma.
Cell culture. Mouse C2C12 myoblasts (ATCC) were maintained in Dulbec-
co’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum, 50 units/ml penicillin, and 50 g/ml streptomycin. When cells reached
conﬂuence, the medium was switched to the differentiation medium contain-
ing DMEM and 2% horse serum, which was changed every other day. After 4
additional days, the differentiated C2C12 cells had fused into myotubes.
Lipid-containing media were prepared by conjugation of FFAs with FFA-free
BSA, using a method modiﬁed from that described by Chavez et al. (18).
Brieﬂy, FFAs were dissolved in ethanol and diluted 1:100 in DMEM containing
2% (wt/vol) fatty acid–free BSA. Myotubes were incubated for 16 h in
serum-free DMEM containing 2% BSA in either the presence (FFA-treated
cells) or absence (control cells) of FFAs. Cells were then incubated with 100
nmol/l insulin for 10 min. Following incubation, RNA was extracted from
myotubes as described below.
Measurements of mRNA. Levels of PGC-1 and - mRNA were assessed by
RT-PCR, as previously described (19). Total RNA was isolated by using the
Ultraspec reagent (Biotecx, Houston). The total RNA isolated by this method
was undegraded and free of protein and DNA contamination. The sequences
of the sense and antisense primers used for ampliﬁcation were PGC-1,
5-CCCGTGGATGAAGACGGATTG-3 and 5-GTGGGTGTGGTTTGCTGCATG-
3; PGC-1,5 -CCTTTATCTGTGCCCCCCAGC-3 and 5-CAAGGCCGCT
GACTTCTGGAA-3; and Aprt (adenosyl phosphoribosyl transferase), 5-
GCCTCTTGGCCAGTCACCTGA-3 and 5-CCAGGCTCACACACTCCACCA-3.
Ampliﬁcation of each gene yielded a single band of the expected size (PGC-1:
228 bp, PGC-1: 185 bp, and Aprt: 329 bp). Preliminary experiments were
carried out with various amounts of cDNA to determine nonsaturating
conditions of PCR ampliﬁcation for all the genes studied. Therefore, under
these conditions, relative quantiﬁcation of mRNA was assessed by the RT-PCR
method described in this study (20). Radioactive bands were quantiﬁed by
video-densitometric scanning (Vilbert Lourmat Imaging). The results for the
expression of speciﬁc mRNAs are always presented relative to the expression
of the control gene (Aprt).
Determination of ceramide levels. The content of ceramides in skeletal
muscle and C2C12 myotubes was determined by the diacylglycerol kinase
method. Brieﬂy, lipids were extracted from 50 mg skeletal muscle with 600
l chloroform, methanol, and 1 N HCl (100:100:1). After agitation and
centrifugation, the lower phase containing the chloroform-extracted lipids
was transferred to a new microfuge tube. Chloroform was evaporated under
an N2 stream. Dried lipids were resuspended in 300 l of 0.1 N KOH in
methanol and incubated for1ha t37°C to eliminate diacylglycerol. Then, 300
l PBS were added and lipid extraction was repeated as indicated above.
Lipids were resuspended in 100 l of reaction buffer (150 g/100 l cardio-
lipin, 280 mol/l diethylenetriaminepentaacetic acid, 51 mmol/l octyl -D-
glucopyranoside, 50 mmol/l NaCl, 51 mmol/l imidazol, 1 mmol/l EDTA, 12.5
mmol/l MgCl2, 2 mmol/l dithiothreitol, 0.7% glycerol, 70 mol/l -mercapto-
ethanol, 500 mol/l ATP, and 5 Ci/100 l[ -
32P]ATP), and 35 ng of
diacylglycerol kinase was added to each sample. Reactions were incubated at
30°C for 30 min and stopped by the addition of 170 l of stop buffer (135
mmol/l NaCl, 1.5 mmol/l CaCl2, 0.5 mmol/l glucose, and 10 mmol/l HEPES, pH
7.2) and 30 l of 100 mmol/l EDTA. Lipids were extracted again with 1 ml
chloroform, methanol, and 1 N HCl (100:100:1), resuspended in 40 l
chloroform, spotted onto silica gel TLC plates (Whatman), and resolved using
chloroform:methanol:acetic acid (65:15:5) as a solvent. Plates were measured
in a PhosphoImager (BioRad). Quantiﬁcation of ceramide mass was obtained
by comparison with a standard curve ranging from 0 to 1,000 pmol ceramide-
1-phosphate (Sigma), which was processed in parallel to the samples.
Isolation of nuclear extracts and electrophoretic mobility shift
assay. Nuclear extracts were isolated according to Andrews et al. (21).
Electrophoretic mobility shift assay (EMSA) was performed using double-
stranded oligonucleotides (Promega, Madison, WI) for the consensus binding
site of the nuclear factor-B (NF-B) nucleotide (5AGTTGAGGGGACTTTC
CCAGGC-3). Oligonucleotides were labeled in the following reaction: 2 lo f
oligonucleotide (1.75 pmol/l), 2 lo f5  kinase buffer, 1 l of T4 polynu-
cleotide kinase (10 units./l), and 2.5 l[ -
32P] ATP (3,000 Ci/mmol at 10
mCi/ml) incubated at 37°C for 1 h. The reaction was stopped by adding 90 l
of TE buffer (10 mmol/l Tris-HCl, pH 7.4, and 1 mmol/l EDTA). To separate the
labeled probe from the unbound ATP, the reaction mixture was eluted in a
Nick column (Pharmacia, Sant Cugat, Spain) according to the manufacturer’s
instructions. Five micrograms of crude nuclear protein were incubated for 10
min on ice in binding buffer [10 mmol/l Tris-HCl, pH 8.0, 25 mmol/l KCl, 0.5
mmol/l dithiothreitol, 0.1 mmol/l EDTA, pH 8.0, 5% glycerol, 5 mg/ml BSA, 100
g/ml tRNA, and 50 g/ml poly(dI-dC)] in a ﬁnal volume of 15 l. The labeled
probe (60,000 cpm) was added and the reaction incubated for 15 min at
room temperature. Where indicated, speciﬁc competitor oligonucleotide was
added before the labeled probe and incubated for 10 min on ice. p65 antibody
was added 15 min before incubation with the labeled probe at 4°C. Protein-
DNA complexes were resolved by electrophoresis at 4°C on a 5% acrylamide
gel and subjected to autoradiography.
Immunoblotting. To obtain total proteins, C2C12 myotubes were homoge-
nized in cold lysis buffer (5 mmol/l Tris-HCl, pH 7.4, 1 mmol/l EDTA, 0.1
mmol/l phenylmethylsulfonyl ﬂuoride, 1 mmol/l sodium orthovanadate, and
5.4 g/ml aprotinin). The homogenate was centrifuged at 10,000g for 30 min at
4°C. Protein concentration was measured by the Bradford method. Total and
nuclear proteins (30 g) were separated by SDS-PAGE on 10% separation gels
and transferred to Immobilon polyvinylidene diﬂouride membranes (Milli-
pore, Bedford, MA). Western blot analysis was performed using antibodies
against total MEK1/2, phospho-MEK1/2 (Ser
217/221), total ERK1/2, and phos-
pho-ERK1/2 (Thr
202/Tyr
204), pan–protein kinase C (PKC) (Cell Signaling
Technology, Beverly, MA), PGC-1 (Chemicon, Temecula, CA), -actin, and
-tubulin (Sigma). Detection was achieved using the EZ-ECL chemilumines-
cence detection kit (Biological Industries, Beit Haemek, Israel). The equal
loading of proteins was assessed by red phenol staining. The size of detected
proteins was estimated using protein molecular mass standards (Invitrogen,
Barcelona, Spain).
Statistical analyses. Results are expressed as the mean 	 SD of ﬁve
separate experiments. Signiﬁcant differences were established by either the
Student’s t test or one-way ANOVA, according to the number of groups
compared, using the computer program GraphPad Instat (GraphPad Software
V2.03; GraphPad Software, San Diego, CA). In the latter case, when signiﬁcant
variations were found, the Tukey-Kramer multiple comparisons test was
performed. Differences were considered signiﬁcant at P 
 0.05.
RESULTS
Palmitate, but not oleate, reduces PGC-1 mRNA
levels in skeletal muscle cells. To study the effects of
FFA on PGC-1 expression in C2C12 skeletal muscle cells,
we chose the saturated FFA palmitate (16:0) and the
monounsaturated FFA oleate (18:1 n-9), which are among
the most common fatty acids (22). Because we recently
observed that exposure of C2C12 skeletal muscle cells to
palmitate for 16 h leads to reduced insulin-stimulated
glucose uptake (19), we used this experimental condition
to evaluate the effects of palmitate and oleate on PGC-1
expression. Skeletal muscle cells exposed to 0.75 mmol/l
palmitate showed a 66% (P 
 0.001) reduction in PGC-1
expression compared with control cells, whereas the
reduction attained by the same concentration of oleate did
not reach signiﬁcance (Fig. 1A). The effects of palmitate on
PGC-1 expression in skeletal muscle cells were speciﬁc,
since neither palmitate nor oleate affected the expression
of PGC-1 (Fig. 1B). Further, we studied the time response
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palmitate treatment for 1 h did not signiﬁcantly affect
PGC-1 mRNA expression, a slight increase was observed
after four (twofold, P 
 0.001) and 8 h (1.5-fold, P 

0.001), reaching a deep reduction after 16 h of treatment
(Fig. 1C). In contrast to PGC-1, a time course study with
palmitate did not show changes in PGC-1 expression
(Fig. 1D). The reduction in mRNA expression was corre-
lated with protein levels, since Western immunoblot anal-
ysis revealed that skeletal muscle cells exposed to
palmitate for 16 h showed a signiﬁcant reduction (55%, P 

0.01) in PGC-1 protein expression (Fig. 1E).
Ceramides and PKC activation are not involved in
palmitate-mediated PGC-1 downregulation in skel-
FIG. 1. Palmitate, but not oleate, downregulates PGC-1 mRNA levels in skeletal muscle cells. Analysis of the mRNA levels of PGC-1 (A) and
PGC-1 (B) in C2C12 myotubes incubated in the presence or in the absence of the indicated FFAs (16 h, 0.75 mmol/l). A total of 0.5 g of total
RNA was analyzed by RT-PCR. A representative autoradiogram and quantiﬁcation, normalized to the APRT mRNA levels, are shown. Data are
expressed as the mean  SD of ﬁve different experiments. ***P < 0.001 vs. control cells. Time course of palmitate effects on PGC-1 (C) and
PGC-1 (D) mRNA levels in C2C12 myotubes incubated with 0.75 mmol/l palmitate for the indicated time points. A representative autoradiogram
and quantiﬁcation, normalized to the APRT mRNA levels, are shown. Data (mean  SD of ﬁve different experiments) are expressed as the relative
increase to control cells at the same time point. ***P < 0.001 vs. control cells. E: Nuclear extracts from C2C12 myotubes incubated in the
presence or in the absence of 0.75 mmol/l palmitate for 16 h were assayed for Western blot analysis with PGC-1 and -tubulin antibodies. Data
are expressed as means  SD of three different experiments normalized to -tubulin levels. **P < 0.01 vs. control cells.
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sphingolipid synthesis, palmitate treatment may result in
enhanced ceramide synthesis and apoptosis (23). Thus, to
gain further insight into the mechanism by which palmi-
tate downregulates PGC-1 mRNA levels, we tested the
effects of one inhibitor of de novo ceramide synthesis.
The initial step in ceramide synthesis is the formation
of 3-ketodihydrosphingosine from palmitoyl-CoA and L-
serine. This step is inhibited by the sphingosine analog
ISP1 at picomole concentrations (24). To further clarify
the potential involvement of ceramides, we treated C2C12
skeletal muscle cells with C2-ceramide, a cell-permeable
ceramide analog. First, we evaluated the effects of palmi-
tate, ISP1, and C2-ceramide on the intracellular concentra-
tions of ceramides. Incubation of C2C12 myotubes with
palmitate and the C2-ceramide analog enhanced ceramide
levels (4.5- and 2.7-fold induction, respectively), whereas
coincubation of the cells with palmitate and ISP1 pre-
vented the increase in the levels of these lipid mediators
(Fig. 2A). Regarding the expression of PGC-1, coincuba-
tion of the cells with palmitate in the presence of ISP1 did
not affect the fall (69%, P 
 0.001) in the mRNA levels of
this coactivator attained by palmitate (Fig. 2B). Similarly,
the addition of 50 mol/l C2-ceramide did not modify
PGC-1 mRNA levels (Fig. 2B). Overall, these data suggest
that de novo ceramide synthesis is not involved in the
effects of palmitate on PGC-1 expression.
As elevations in plasma FFAs may lead to diacylglycer-
ol-mediated activation of PKC (25), we subsequently
investigated whether palmitate-mediated PGC-1 down-
regulation involved PKC activation. To test this hypothe-
sis, we used two approaches. We ﬁrst veriﬁed the effects of
calphostin C, a strong and speciﬁc inhibitor of PKC (26), on
PGC-1 downregulation caused by palmitate in C2C12 myo-
tubes. Cells were preincubated with calphostin C (100
mol/l) for 30 min and subsequently stimulated with 0.75
mmol/l palmitate for 16 h. We then pretreated cells with 0.5
mol/l phorbol myristic acid (PMA) for 24 h before stimula-
tion with palmitate. This long-term pretreatment with PMA
causes PKC downregulation (27,28) (Fig. 2C). As shown in
Fig. 2D, no changes were observed in PGC-1 mRNA levels
in those cells exposed to palmitate coincubated with either
calphostin C or PMA. These data seem to rule out the
involvement of PKC activation in palmitate-mediated PGC-1
downregulation in skeletal muscle cells. Finally, since we
have recently reported that skeletal muscle cells exposed to
palmitate secrete IL-6 into culture media (19), and that this IL
may affect cell metabolism, we determined whether IL-6 was
involved in palmitate-mediated PGC-1 downregulation us-
ing an anti–IL-6 antibody. While treatment with palmitate led
to a reduction in PGC-1 mRNA levels, coincubation with
anti–IL-6 antibody did not prevent this change (Fig. 2E).
Activation of the ERK-MAPK pathway and NF-B are
involved in palmitate-mediated PGC-1 downregula-
tion. Since activation of the ERK-MAPK cascade is report-
edly activated by palmitate (29), we next evaluated its
involvement in the downregulation of PGC-1 following
palmitate exposure. We ﬁrst conﬁrmed that under our
conditions, exposure of the cells to palmitate led to
MEK1/2 activation. Subsequent immunoblotting detection
of total and phosphorylated MEK1/2 (Fig. 3A) revealed
that palmitate treatment activated this pathway (1.75-fold
induction, P 
 0.05), whereas no signiﬁcant changes were
observed in cells exposed to oleate. To clearly demon-
strate the involvement of the ERK-MAPK cascade in
PGC-1 downregulation in those cells incubated with
palmitate, we utilized pharmacological inhibitors to block
the upstream regulators of ERK1/2. We assayed the effects
of two MEK1/2 inhibitors: PD98059, a more general inhib-
itor of this pathway, and U0126, a more potent and speciﬁc
ERK1/2 inhibitor that binds to MEK, thereby inhibiting its
catalytic activity as well as phosphorylation of ERK1/2.
The reduction in PGC-1 mRNA levels achieved by palmi-
tate (58%, P 
 0.001 vs. control cells) was abrogated when
the cells were coincubated with either PD98059 (19%, P 

0.01 vs. palmitate-treated cells) or U0126 (9%, P 
 0.001 vs.
palmitate-treated cells) (Fig. 3B), indicating that activation
of the MAPK-ERK cascade was involved in the decrease of
this coactivator following palmitate treatment. As control,
we veriﬁed that U0126 treatment condition inhibited
ERK1/2 activation (Fig. 3C).
Since we have previously reported that C2C12 exposure
to palmitate activates NF-B (19), and activation of the
ERK-MAPK cascade may inﬂuence NF-B activation in
skeletal muscle (30), we next determined whether activa-
tion of this transcription factor was involved in palmitate-
mediated PGC-1 downregulation. We ﬁrst conﬁrmed
whether palmitate-mediated NF-B activation involved
activation of the ERK-MAPK cascade by performing EMSA
studies using nuclear extracts from palmitate-treated cells
incubated either in the presence or in the absence of
U0126. The NF-B probe formed two complexes with
nuclear proteins (complexes I and II) (Fig. 4A). Speciﬁcity
of the two DNA-binding complexes was assessed in com-
petition experiments by adding an excess of unlabeled
NF-B oligonucleotide. NF-B binding activity, primarily
involving speciﬁc complex II, increased in nuclear extracts
from palmitate-treated cells. However, U0126 prevented
this increase in NF-B binding activity, indicating that in
the presence of this MEK1/2 inhibitor, palmitate failed to
induce this transcription factor. The addition of antibody
against the p65 subunit of NF-B supershifted complex II,
indicating that this band was mainly comprised of this
subunit. No changes were observed in the DNA binding of
nuclear proteins to an Oct-1 probe, indicating that the
increase observed for the NF-B probe was speciﬁc (data
not shown). As control, we veriﬁed that the NF-B inhib-
itor parthenolide prevented palmitate-induced NF-B acti-
vation (Fig. 4A). Since palmitate-induced NF-B activation
is mediated by degradation of inhibitor of B( I B) 
(19,31), we examined the effects of palmitate and U0126 on
IB protein levels. Whereas cells exposed to palmitate
showed reduced IB protein levels, this reduction was
prevented in cells coincubated with palmitate and U0126
(Fig. 4B). The effect of palmitate on IB protein levels
was speciﬁc for this saturated fatty acid, given that oleate
did not signiﬁcantly affect the levels of this protein (Fig.
4C). To clearly demonstrate whether NF-B activation was
involved in palmitate-mediated PGC-1 downregulation,
we used the NF-B inhibitor parthenolide, which speciﬁ-
cally inhibits NF-B activation by preventing IB degrada-
tion (32). The reduction in PGC-1 mRNA expression
levels attained by palmitate (51%, P 
 0.001 vs. control
cells) was prevented when C2C12 cells were coincubated
with parthenolide (27%, P 
 0.05 vs. palmitate-exposed
cells) (Fig. 4D). In agreement with the results obtained for
mRNA expression, coincubation of the cells with palmi-
tate, in either the presence of U0126 or parthenolide,
prevented the reduction in PGC-1 protein levels (Fig. 4E).
Overall, these results suggest that PGC-1 downregulation
in skeletal muscle cells following palmitate exposure is
regulated by the ERK-MAPK–NF-B pathway.
PALMITATE DOWNREGULATES PGC-1
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Skeletal muscle insulin resistance is the major character-
istic of type 2 diabetes (33). Insulin resistance correlates
more strongly with intramyocellular lipid levels than with
any other factor, including BMI or percent body fat
(7,34,35). Despite these data, the mechanisms by which
elevated FFA levels cause intramyocellular lipid accumu-
lation and insulin resistance are not well understood.
Elevated FFAs may affect the expression of several genes,
contributing to intramyocellular lipid accumulation and,
FIG. 2. Ceramides and PKC activation are not involved
in palmitate-mediated downregulation of PGC-1 in
skeletal muscle cells. Measurement of ceramide (A) and
PGC-1 mRNA (B) levels in C2C12 myotubes incubated
(16 h) with 0.75 mmol/l palmitate in the presence or in
the absence of 100 nmol/l ISP1, an inhibitor of de novo
ceramide synthesis. Cells were also treated with 50
mol/l C2-ceramide, a cell-permeable ceramide analog.
Lipid extracts were prepared and assayed for ceramides
as detailed under RESEARCH DESIGN AND METHODS. Data are
expressed as the mean  SD of three different experi-
ments. A total of 0.5 g of total RNA was analyzed by
RT-PCR. A representative autoradiogram and quantiﬁ-
cation, normalized to the APRT mRNA levels, are
shown. C: Total protein extracts from C2C12 myotubes
incubated with 0.75 mmol/l palmitate for 16 h in the
presence or in the absence of 500 nmol/l PMA were
assayed for Western blot analysis with pan-PKC and
-actin antibodies. Data are expressed as the mean 
SD of three different experiments. C2C12 myotubes
were incubated (16 h) with 0.75 mmol/l palmitate in the
presence or in the absence of either 100 mol/l calphos-
tin C, 500 nmol/l PMA (D), or 5 g/ml of anti–IL-6
antibody (E), and the mRNA levels of PGC-1 were
analyzed. Data are expressed as the mean  SD of ﬁve
different experiments. **P < 0.01 and ***P < 0.001 vs.
control cells; ###P < 0.001 vs. palmitate-treated cells.
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Interestingly, insulin-resistant states have been associated
in skeletal muscle with decreased expression of PGC-1,a
transcriptional coactivator promoting oxidative capacity
in this tissue (10,13,16). Thus, overexpression of PGC-1
in cultured myoblasts increases mitochondrial biogenesis
and oxidative respiration (36). Moreover, muscle-speciﬁc
overexpression of PGC-1 in transgenic mice results in
enhanced mitochondrial biogenesis and more slow-twitch
(type I) ﬁber formation (37). Although PGC-1 expression
has been inversely correlated with plasma FFA levels (13)
and lipid infusion decreased PGC-1 in skeletal muscle (16),
FIG. 3. The ERK-MAPK pathway is involved in palmitate-mediated PGC-1 downregulation in skeletal muscle cells. C2C12 myotubes were
incubated (16 h) with 0.75 mmol/l fatty acids in the presence or in the absence of 100 mol/l PD98059 or 10 mol/l U0126, inhibitors of the
ERK-MAPK pathway. A: Analysis of MEK 1/2 activity determined by immunoblotting. The level of phosphorylated MEK1/2 was normalized against
total MEK1/2 in each sample. B: Analysis of the mRNA levels of PGC-1. A total of 0.5 g total RNA was analyzed by RT-PCR. A representative
autoradiogram and quantiﬁcation, normalized to the APRT mRNA levels, are shown. Data are expressed as the mean  SD of ﬁve different
experiments. *P < 0.05 and ***P < 0.001 vs. control cells; ##P < 0.01 vs. palmitate-treated cells. C: Analysis of ERK and phospho-ERK by
immunoblotting of total protein extracts from C2C12 myotubes incubated with 0.75 mmol/l palmitate for 16 h in the presence or in the absence
of 10 mol/l U0126. The level of phosphorylated ERK1/2 was normalized against total ERK1/2 in each sample. Data are expressed as the mean 
SD of three different experiments. ###P < 0.001 vs. palmitate-treated cells.
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PGC-1 or the biochemical pathways involved. Here, we
report that the FFA palmitate reduces PGC1- expression
in skeletal muscle cells through a mechanism involving
activation of the ERK-MAPK–NF-B pathway.
The results presented here conﬁrm the role that ele-
vated FFA plays in the downregulation of PGC-1 in
skeletal muscle cells. It is worth noting that the type of
fatty acid may be central to the development of insulin
resistance. In this study, we used the saturated fatty acid
palmitate. Intramuscular triglycerides and their palmitate
fraction of these triglycerides, though not the oleate
fraction, negatively correlated with insulin-stimulated glu-
cose uptake (38). Interestingly, simultaneous to the effects
of PGC-1 on mitochondrial respiration in skeletal muscle
cells, this coactivator also induces gene expression for the
insulin-sensitive glucose transporter (GLUT4) and in-
creases glucose uptake (39). These data suggest that the
palmitate fraction of fatty acids present in intramuscular
triglycerides, which is elevated in the muscle of obese
FIG. 4. NF-B activation is involved in palmitate-mediated PGC-1 downregulation in skeletal muscle cells. A: The MEK1/2 inhibitor U0126 blocks
the action of NF-B by palmitate. C2C12 myotubes were incubated for 16 h with 0.75 mmol/l palmitate in the presence or in the absence of either
10 mol/l U0126 or 10 mol/l parthenolide. An autoradiograph of EMSA performed with a
32P-labeled NF-B nucleotide and crude nuclear protein
extract (NE) is shown. Speciﬁc complexes, based on competition with a molar excess of unlabeled probe, are shown. A supershift analysis
performed by incubating NE with an antibody directed against the p65 subunit of NF-B is also shown. B and C: total protein extracts from C2C12
myotubes incubated for 16 h with either 0.75 mmol/l palmitate or oleate in the presence or in the absence of 10 mol/l U0126 were assayed for
Western blot analysis with IB antibody. D: C2C12 myotubes were incubated (16 h) with 0.75 mmol/l palmitate in the presence or in the absence
of the NF-B inhibitor (10 mol/l) parthenolide. Analysis of PGC-1 mRNA levels. A total of 0.5 g of total RNA was analyzed by RT-PCR. A
representative autoradiogram and quantiﬁcation, normalized to the APRT mRNA levels, are shown. Data are expressed as the mean  SD of ﬁve
different experiments. ***P < 0.001 vs. control cells; #P < 0.05 vs. palmitate-treated cells. E: ERK-MAPK and NF-B inhibitors prevent the
decrease in PGC-1 protein levels in skeletal muscle cells exposed to palmitate. Nuclear extracts from C2C12 myotubes incubated with 0.75 mmol/l
palmitate for 16 h in the presence or in the absence of U0126 (10 mol/l) or parthenolide (10 mol/l) were assayed for Western blot analysis with
PGC-1 and -actin antibodies.
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deleterious effects on muscle glucose and fatty acid me-
tabolism through the decrease in the expression of PGC-
1.
The mechanism by which palmitate reduces PGC-1
mRNA levels in skeletal muscle cells seems to involve
activation of the ERK-MAPK cascade, which in turn acti-
vates NF-B, whereas enhanced ceramide levels and PKC
activation seem not to be implicated. Our results demon-
strate for the ﬁrst time that exposure of skeletal muscle
cells to palmitate leads to PGC-1 downregulation though
a mechanism involving MEK1/2 activation, whereas inhi-
bition of this cascade prevents the fall in PGC-1 expres-
sion caused by palmitate. The results reported here
suggest that MEK activation depends on the type of fatty
acids, since oleate treatment did not result in MEK activa-
tion. However, the mechanisms through which palmitate
treatment results in MEK activation remain to be estab-
lished. Interestingly, it has been reported that the conju-
gated linoleic acid activates MEK in human adipocytes
through unidentiﬁed upstream signal that may involve
activation of membrane proteins or generation of metab-
olites, which, in turn, triggers a signal that activates this
pathway (40). To our knowledge, there are no reports in
the literature addressing the direct effect of either MEK
activation or inhibition on PGC-1 mRNA levels. However,
Watt et al. (41) reported that enhanced PGC-1 mRNA
levels in human skeletal muscle following exercise was
accompanied by a reduction in phospho-ERK levels, sup-
porting the contention that these kinases play a role in
controlling PGC-1 mRNA levels.
Furthermore, our results suggest that NF-B activation
by palmitate is also involved in the regulation of PGC-1
expression in skeletal muscle cells, thereby bolstering the
considerable evidence supporting a link between inﬂam-
mation and type 2 diabetes. This relationship between
palmitate-activated NF-B and PGC-1 downregulation in
skeletal muscle cells is interesting since NF-B has been
linked to the fatty acid–induced impairment of insulin
action in rodent skeletal muscle (42,43), while palmitate-
induced insulin resistance is reportedly prevented by
inhibition of this transcription factor (44). Palmitate may
activate NF-B through several mechanisms. First, it has
been suggested that palmitate activates NF-B by protea-
some-mediated degradation of IB (31). This is consis-
tent with the reported reduction in IB mass after
palmitate treatment shown in this study (Fig. 4B). Second,
MEK1/2 is important for NF-B activation (45), and in this
study we report that palmitate-mediated activation of
MEK1/2 contributes to NF-B activation, a process that is
prevented when MEK1/2 is inhibited. Here, we do not
provide an explanation about how palmitate-mediated
NF-B activation results in PGC-1 downregulation, but
several mechanisms could be involved. Interestingly, while
this study was under evaluation, Hondares et al. (46)
reported the presence of a PPAR response element in the
promoter of the PGC-1 gene. Since MEK activation
decreases PPAR activity by phosphorylating this nuclear
receptor and/or by interfering its transactivation activity
(47), this provides a potential mechanism for the MEK-
mediated downregulation of PGC-1 after palmitate expo-
sure. Similarly, NF-B activation results in reduced PPAR
activity (48), suggesting that this mechanism may also
contribute to the reduction in PGC-1 expression after
palmitate treatment. In agreement with this possibility, we
have reported that skeletal muscle cells exposed to palmi-
tate show reduced PPAR binding activity (49). Further,
since the NF-B inhibitor parthenolide, compared with
MEK inhibitors, only partially reversed the effect of palmi-
tate on PGC-1 expression, this may indicate that a
blockade of upstream targets, i.e., MEK, is required to
completely reverse the effects attained by palmitate or that
additional proteins, such as Akt (50), are involved in the
changes observed.
In summary, we report here that exposure of skeletal
muscle cells to palmitate results in a reduction in PGC-1
expression via a mechanism involving the activation of the
ERK-MAPK–NF-B axis. These results not only conﬁrm
the hypothesis that enhanced plasma FFAs reduce PGC-1
expression but also identify the biochemical pathway
involved, providing an attractive target for therapeutics in
diabetes and related diseases.
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